Breed s Hill Capital LLC Sells 103 Shares of Johnson & Johnson (NYSE:JNJ)

Breed s Hill Capital LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 3.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,808 shares of the company’s stock after selling 103 shares during the quarter. Breed s Hill Capital LLC’s holdings in Johnson & Johnson were worth $410,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in JNJ. Pathway Financial Advisors LLC raised its holdings in Johnson & Johnson by 4.3% in the 4th quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock valued at $852,000 after buying an additional 226 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in Johnson & Johnson by 5.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock valued at $46,685,000 after buying an additional 15,490 shares during the last quarter. Drive Wealth Management LLC raised its holdings in Johnson & Johnson by 4.5% in the 1st quarter. Drive Wealth Management LLC now owns 9,625 shares of the company’s stock valued at $1,523,000 after buying an additional 414 shares during the last quarter. Vestmark Advisory Solutions Inc. raised its holdings in Johnson & Johnson by 12.7% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock valued at $3,070,000 after buying an additional 2,201 shares during the last quarter. Finally, California Public Employees Retirement System increased its position in Johnson & Johnson by 4.9% during the 4th quarter. California Public Employees Retirement System now owns 10,620,264 shares of the company’s stock valued at $1,664,620,000 after purchasing an additional 498,647 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. TD Securities lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. TD Cowen lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Finally, HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Stock Up 0.4 %

JNJ stock traded up $0.62 during midday trading on Thursday, reaching $159.10. 7,237,481 shares of the company’s stock traded hands, compared to its average volume of 7,355,802. The company has a market cap of $382.90 billion, a price-to-earnings ratio of 9.90, a P/E/G ratio of 2.63 and a beta of 0.52. The firm’s fifty day moving average price is $151.88 and its 200-day moving average price is $153.10. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.39.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.80 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.12%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.